Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X
暂无分享,去创建一个
C. C. Bailey | S. Richards | S. M. Richards | J. Chessells | C. Bailey | J. M. Chessells | Bailey Cc
[1] C C Bailey,et al. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials * , 1995, British journal of haematology.
[2] G. Rivera. Advances in therapy for childhood non-B-lymphoblastic leukaemia. , 1994, Bailliere's clinical haematology.
[3] G. Reaman,et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Hancock,et al. Treatment of acute lymphoblastic leukemia : 30 years' experience at St. Jude Children's Research Hospital , 1993 .
[5] H. Sather,et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Richards,et al. Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALLX , 1992, The Lancet.
[7] M. L. Le Beau,et al. Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gelber,et al. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] J. Peto,et al. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood) , 1991, British journal of haematology.
[10] D Cox,et al. The contribution of statistical methods to cancer research , 1991 .
[11] J. Lilleyman,et al. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. , 1991, Archives of disease in childhood.
[12] S. Colan,et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.
[13] J. Shuster,et al. A pilot study of intermediate‐dose methotrexate and cytosine arabinoside, “Spread‐out” or “Up‐front,” in continuation therapy for childhood non‐T, non‐B acute lymphoblastic leukemia a pediatric oncology group study , 1991 .
[14] F. Behm,et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.
[15] J. Lilleyman,et al. Testicular irradiation in childhood lymphoblastic leukaemia , 1990 .
[16] H. Sather,et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Shuster,et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Behm,et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.
[19] C. R. Pinkerton,et al. Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study). , 1987, Archives of disease in childhood.
[20] R. Gelber,et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.
[21] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[22] H. Sather,et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Denis R. Miller,et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG‐141: A report from childrens cancer study group , 1983, Cancer.
[24] L. Freedman,et al. Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.
[25] W. Looney,et al. Solid Tumour Models for the Assessment of Different Treatment Modalities: VII: Single vs Fractionated Doses of 5-Fluorouracil on Two Solid Tumours and Their Hosts , 1978, British Journal of Cancer.
[26] L. Norton,et al. Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.
[27] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[28] G. Henze,et al. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.
[29] Rivera Gk,et al. Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors , 1987 .
[30] M. Schrappe,et al. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.
[31] Walker,et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. , 1986, Blood.